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The 1990s brought a burst of information regarding the structure, expression pattern, and
role in leukocyte migration and adhesion of chemokines and their receptors. At that time,
the FDA approved the first therapeutic antibodies for cancer treatment. A few years later,
it was reported that the chemokine receptors CXCR4 and CCR7 were involved on direct-
ing metastases to liver, lung, bone marrow, or lymph nodes, and the over-expression of
CCR4, CCR6, and CCR9 by certain tumors. The possibility of inhibiting the interaction of
chemokine receptors present on the surface of tumor cells with their ligands emerged
as a new therapeutic approach. Therefore, many research groups and companies began
to develop small molecule antagonists and specific antibodies, aiming to neutralize sig-
naling from these receptors. Despite great expectations, so far, only one anti-chemokine
receptor antibody has been approved for its clinical use, mogamulizumab, an anti-CCR4
antibody, granted in Japan to treat refractory adult T-cell leukemia and lymphoma. Here,
we review the main achievements obtained with anti-chemokine receptor antibodies for
cancer immunotherapy, including discovery and clinical studies, proposed mechanisms of
action, and therapeutic applications.
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INTRODUCTION
Cancer treatment is expanding from non-specific cytotoxic
chemotherapies to targeted therapies. These are focused on
fighting cancer cells, modifying the tumor microenvironment,
or enhancing anti-tumor immunity (1–3). Malignant and stro-
mal cells secrete a variety of proteins, including matrix com-
ponents, proteolytic enzymes, growth factors, pro-inflammatory
cytokines, and chemokines (2, 4). Among them, tumor-associated
chemokines play a central role in cancer biology, favoring leuko-
cyte infiltration, promoting tumor growth, angiogenesis, and
immune evasion (5–10).
Many tumor cells over-express functional chemokine recep-
tors, undetectable on their normal counterparts. These recep-
tors respond to chemokine signals by promoting cell survival,
proliferation, adhesion, or migration, but also direct metastasis
formation on tissues or organs where the corresponding lig-
ands are secreted (9). Since the most common cause of death
in cancer patients are metastases (11, 12), chemokine receptors
expressed on the surface of cancer cells are considered suitable
targets for the generation of new anti-tumor drugs (8, 13–17).
As a consequence, a great effort has been made in the investi-
gation of new drugs targeting chemokine receptors for cancer
treatment. The initial focus was on the development of small
molecules able to inhibit chemokine receptor signaling, although
with limited success (18, 19). Recent achievements in the use of
monoclonal antibodies (mAbs) targeting a variety of molecules
for the treatment of leukemia, breast cancer, colon cancer, and
melanoma (20–23), have contributed to move the efforts onto tar-
geting chemokines and their receptors toward generating specific
antibodies for therapeutic purposes.
The clinical use of an anti-chemokine receptor mAb, moga-
mulizumab, specific for the C–C chemokine receptor type 4
(CCR4) has been granted in Japan for the immunotherapy of
patients with relapsed or refractory CCR4+ adult T-cell leukemia
(ATL) (24). This antibody is currently in phase II and III clin-
ical trials in Europe and the USA for the treatment of patients
with ATL, cutaneous T-cell lymphoma (CTCL), or peripheral T-
cell lymphoma (PTCL) (24, 25). In addition, antibodies specific
for the CCR2 and CXCR4 receptors are also being evaluated in
clinical trials, while antibodies against many other chemokine
receptors have shown effectiveness in different xenograft models
of cancer (26–38).
CHEMOKINES AND THEIR RECEPTORS IN CANCER
Chemokines are a family of small chemotactic cytokines, with 44
members in humans, which generate soluble or immobilized gra-
dients that direct the movement of cells (39, 40). Chemokines, by
controlling leukocyte trafficking and recruitment, play a central
role in homeostasis and the maintenance of innate and acquired
immunity (41). They are essential in mammalian development
and organogenesis, and like other cytokines stimulate cell growth,
differentiation, and activation (16). Chemokines are subdivided
in four major groups, namely CX3C, CXC, CC, and C, based
on the number and spacing of conserved cysteine residues on
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their N-terminus (39, 42). These proteins are functionally known
as “inflammatory” or “homeostatic,” based on whether they are
released upon inflammatory stimuli or constitutively secreted by
cells located in lymphoid organs, respectively (43).
The biological effects of chemokines are exerted through their
interaction(s) with specific surface receptors (chemokine recep-
tors), structurally belonging to the seven transmembrane domain
G protein-coupled receptor superfamily (GPCR). The chemokine
receptor family contains 24 members in humans and can be sub-
divided, based on the class of chemokines they bind, into four
subfamilies (CX3CR, CXCR, CCR, and XCR) all of them activat-
ing G proteins, and one subfamily (ACKR), containing 6 atypical
receptors, unable to activate G proteins upon ligand binding (39,
44). It is worth to note that the chemokine/chemokine receptor
system has redundancy, since some particular chemokines are able
to bind to multiple receptors, and vice versa (41).
Chemokines and their receptors have been implicated in
the pathogenesis of many inflammatory and infectious diseases
including rheumatoid arthritis, multiple sclerosis, asthma, ather-
osclerosis, malaria, and AIDS (15, 16, 45, 46), but also in cancer (5,
47). Expression levels of chemokines and their receptors are often
deregulated in malignant cells, due, for example, to inactivation of
tumor suppressor genes, constitutive activation of oncogenes, or
altered expression of transcription factors (8, 48–50).
Expression of chemokines and their receptors play a dual role in
tumorigenicity. On the one hand, chemokines secreted by either
the cancer-initiating cells or the normal cells surrounding them
can help limiting tumor development by increasing leukocyte
migration toward the site, and inducing long-term anti-tumor
immunity. On the other hand, they may facilitate survival, prolif-
eration, and metastatic potential of tumor cells (6, 10, 51–54).
The initially secreted chemokines at the tumor site play a key
role defining the composition of the tissue stroma and recruiting
tumor infiltrating leukocytes bearing specific chemokine recep-
tors (CXCR1, CXCR2, CCR2, CCR4, or CCR5, among others)
(7). Therefore, many chemokines are pro-inflammatory for most
tumors (4) and have key functions in tumor angiogenesis (55, 56).
For example, CXCL12 (SDF-1), the only known ligand for CXCR4,
is a potent endothelial cell chemoattractant (57, 58).
Tumor cells are able to hijack the chemokine recep-
tor/chemokine system on their own benefit. Strikingly, they “con-
vert” infiltrating leukocytes into immuno-tolerant allies (59–61),
since they are able to (i) attract suppressor T-cells and neu-
trophils (62–65), (ii) hijack immature dendritic cells, avoiding
their migration toward the lymph nodes and therefore antigen pre-
sentation, favoring a tolerogenic profile (66), and (iii) participate
in the recruitment and induction of myeloid-derived suppressor
cells (67).
The most frequently over-expressed chemokine receptor in
malignant cells is CXCR4 (68). It is present in over 23 different
types of human cancer, including those with the highest incidence,
such as lung, brain, prostate, breast, pancreas, ovarian, colorectal,
leukemia, and melanomas (63). CXCR4 expression on malignant
cells correlates with cell survival, tumor growth, angiogenesis,
higher metastatic potential, and resistance to therapeutic agents
(35, 69–76). Its ligand, CXCL12, is secreted in large amounts by
bone marrow, lymph node, liver, and lung cells.
CXCR4 and CXCL12 can be used to exemplify the complexity
of the chemokine/chemokine receptor networks in cancer. Unlike
other chemokine receptors that have several ligands, it was orig-
inally thought that CXCL12 was the unique ligand for CXCR4
and that it was unable to bind any other receptor. In 2005, it
was reported that CXCL12 was also able to bind ACKR3 (for-
merly CXCR7) with 10 times higher affinity (77–80). ACKR3 has
two ligands CXCL12 and CXCL11. This receptor, in addition to
important roles in embryonic development and cardiovascular
functions (79, 81, 82), also participates in breast and lung tumori-
genesis and metastasis (78). The complexity of this network is
even higher since the ACKR3 ligand CXCL11 is also shared by
CXCR3, a chemokine receptor with two isoforms (A and B),
over-expressed in many tumors, and able to bind other ligands
(CXCL9 or CXCL10) (83). Altered CXCR3 isoform expression reg-
ulates cancer cell migration and invasion (84). Indeed, CXCL11
promotes proliferative signals through binding to CXCR3-A or
ACKR3, whereas binding to CXCR3-B results in growth inhibitory
functions (85). The complexity of several ligands being able to bind
different receptors or different isoforms of a given receptor, having
different outcomes (proliferation vs. growth inhibition), should be
taken into account on any pharmacological intervention.
There is broad evidence indicating that the expression of a
determined chemokine receptor by a tumor preferentially directs
its metastasis to the organs in which the corresponding chemokine
ligand is secreted (10, 86), some of them are detailed in Table 1.
Extensive revision of the expression and actions of chemokine
receptors in cancer exceeds the focus of this review and can be
obtained from recent reviews in Ref. (86, 87).
ANTIBODY-BASED DRUGS FOR CANCER THERAPY
Monoclonal antibodies are relatively large molecules with clear
advantages for their use as therapeutic drugs. These are related to
their long half-life in blood, their ability to establish specific and
high affinity interactions with other molecules or with immune
system cells, together with their relatively low toxicity (207–210).
Drugs based on mAbs are, however, more difficult and expensive to
develop and produce, and less convenient to administer than small
molecule drugs. Indeed, they are able to bridge the target antigen,
or cells bearing the antigen, with the innate or acquired cellu-
lar immune response (211). These characteristics, together with
the development of antibody humanization techniques, phage
display systems, advanced high-throughput screening methods,
and transgenic mice that produce human antibodies, led to many
pharmaceutical companies to invest on therapeutic mAbs. This,
together with the clinical success of therapeutic antibodies during
the last decade, has led to an exponential increase on the number of
mAbs for cancer treatment. For instance, in oncology,chimeric and
humanized mAb that entered clinical studies had approval success
rates four times greater than new chemical entities, including small
molecule agents (211–213). The development of therapeutic anti-
bodies is growing fast, and includes many best-selling drugs for
the treatment of cancer (rituximab, bevacizumab, trastuzumab)
or immunological diseases (adalimumab, infliximab) (214).
Therapeutic antibodies for cancer treatment can be classified,
on the basis of the targets they are directed to, into: (i) surface-
expressed molecules on the tumor cell; (ii) cytokines, growth
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Table 1 | Human chemokine receptors and related metastases.
Chemokine
receptora
Ligandsa Type of cancerb Metastasis
sites
References
CXCR1 CXCL5, CXCL6, CXCL8 Melanoma, breast cancer, ovarian cancer, prostate cancer (88–94)
CXCR2 CXCL1, CXCL2, CXCL3,
CXCL5, CXCL6, CXCL7,
CXCL8
Melanoma, breast cancer, ovarian cancer, prostate, renal cell
carcinoma, pancreatic cancer, esophageal cancer
Lung (33, 88–92,
94–100)
CXCR3 CXCL4L1, CXCL4,
CXCL9, CXCL10,
CXCL11
Melanoma, breast cancer, colorectal cancer, osteosarcoma, ALL,
B-cell CLL
Lung, lymph
nodes
(101–111)
CXCR4 CXCL12 Melanoma, breast cancer, ovarian cancer, prostate cancer, glioma,
neuroblastoma, squamous cell cancer, head and neck cancer,
esophageal cancer, stomach cancer, bladder cancer, pancreatic
cancer, colorectal cancer, renal cancer, osteosarcoma, NSCLC,
AML, FCCL, ALL, CLL, NHL, multiple myeloma
Bone marrow,
lymph nodes, lung,
liver, peritoneum
(35, 63, 69, 70,
73, 86, 107, 110,
112–148)
CXCR5 CXCL13 Squamous cell cancer, B-cell CLL, mantle lymphoma Bone, lymph node,
peripheral nerves
(129, 149, 150)
CCR1 CCL3, CCL4, CCL5,
CCL6, CCL7, CCL8,
CCL13, CCL14, CCL15,
CCL16, CCL23
Colorectal cancer Liver (151–154)
CCR2 CCL2, CCL5, CCL7,
CCL8, CCL13, CCL16
Breast cancer, prostate cancer, multiple myeloma Bone marrow, lung (155–158)
CCR3 CCL4, CCL5, CCL7,
CCL11, CCL13, CCL15,
CCL24, CCL26, CCL28
Renal carcinoma, CTCL (159, 160)
CCR4 CCL17, CCL22 CTCL, ATL, ATLL, PTCL Skin (161–164)
CCR5 CCL3, CCL4, CCL5,
CCL7, CCL14, CCL16
Breast cancer, colorectal cancer Liver, lung (165, 166)
CCR6 CCL20 Colorectal cancer Liver (167–169)
CCR7 CCL19, CCL21 Melanoma, breast cancer, non-small cell lung cancer, lung cancer,
head and neck cancer, esophageal squamous cell carcinoma,
stomach cancer, gastric carcinoma, colorectal cancer, B-cell
CLL, CLL
Lymph nodes (105, 113, 115,
129, 133, 135,
136, 138, 141,
170–179)
CCR9 CCL25 Melanoma, breast cancer, prostate cancer, T-ALL Small intestine (86, 180–186)
CCR10 CCL27, CCL28 Melanoma, CTCL Skin (136, 164,
187–191)
CX3CR1 CX3CL1 Breast cancer, prostate cancer, colorectal cancer, PDAC Bone marrow,
peripheral nerves,
brain
(149, 150,
192–200)
ACKR3 CCL11, CCL12 Breast cancer, NSCLC, rhabdomyosarcoma Lung, bone
marrow, liver, brain
(201–205)
ACKR6 CCL18 Breast cancer Lung, liver (206)
aChemokine receptors and their corresponding chemokines, following the updated nomenclature in Bachelerie et al. (39).
bTypes of cancer that over-express certain chemokine receptors.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATL, adultT-cell leukemia; ATLL, adultT-cell leukemia/lymphoma; CLL, chronic lymphocytic leukemia;
CTCL, cutaneous T-cell lymphoma; FCCL, follicular center lymphoma; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal
adenocarcinoma; PTCL, peripheral T-cell lymphoma; T-ALL, T-cell acute lymphoblastic leukemia.
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factors, surface receptors, or other molecules required for tumor
and/or stroma proliferation or survival; and (iii) immune cell
surface molecules that regulate tumor cell recognition and elim-
ination. Conversely, on the basis of their mechanisms of action,
they would be classified as mAbs that kill tumor cells through:
(i) direct effects (host independent) (i.e., inhibiting receptor-
ligand binding, and/or activating intracellular signaling); (ii) indi-
rect effects (host dependent) modulating the immune response
[i.e., antibody-dependent cell-mediated cytotoxicity (ADCC),
complement-dependent cytotoxicity (CDC), antibody-dependent
phagocytosis (ADP), etc.]; (iii) being used as molecular carriers,
specifically delivering cytotoxic agents, toxins, or radio-isotopes,
to target malignant cells (209); and (iv) targeting regulatory mole-
cules on host immune system cells. Therapeutic mAbs often exert
their anti-tumoral functions simultaneously using several of these
mechanisms of action (29).
During the last years, a broad effort has been centered on tar-
geting regulatory molecules from the host immune system that act
as “immune checkpoints” with mAbs. Examples are ipilimumab,
a mAb directed against the receptor cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4), or pembrolizumab (MK-3475),
a mAb against the programed cell death protein-1 (PD-1), used
for the treatment of metastatic melanomas (215). These mAbs
inhibit the negative regulatory signals triggered by CTLA-4 or
PD-1, enhancing T-cell responses against the tumor (215–218).
Other mAbs, recognizing antigens on the antigen presenting cells,
such as an agonist mAb against the stimulatory protein CD40
have also been postulated to harbor therapeutic effects against
tumors (218, 219).
Antibodies have been generated against chemokines and their
receptors. Since chemokine receptors have seven domains embed-
ded in the cell membrane, their solubilization for obtaining the
required amounts in the native conformation and the correct
orientation for their use as immunogens is extremely difficult
(220). These characteristics, together with their multiple post-
translational modifications, low cell surface expression levels and
lack of stability of their native conformations, make it particu-
larly challenging to generate antibodies against them. Synthetic
peptides had been used as immunogens, although this approach
usually generates mAbs with low affinity and poor antagonistic
effects (221, 222). The development of sophisticated strategies
that preserve the protein native conformation during purifica-
tion, along with advances in the synthesis of peptides with pre-
designed structures,genetic immunization techniques,production
of chemokine receptor-containing liposomes or lipoparticles, or
over-expression of receptors in viral particles, enabled the gener-
ation of antibodies with higher affinities and/or able to function
as strong antagonists (220). The expected in vivo efficacy of mAbs
anti-chemokine receptors is higher than those against chemokines,
since a cell surface-restricted receptor molecule is more efficiently
targeted than delocalized secreted chemokines (220, 223). In addi-
tion, chemokine receptor targeting offers the possibility not only
of blocking the signaling by preventing ligand binding to its recep-
tor but also of tagging the tumor cells with the antibody, to trigger
the host immune response against them.
Anti-chemokine receptor antibodies have been evaluated for
the treatment of inflammatory and infectious diseases, including
anti-CCR2 for rheumatoid arthritis and atherosclerosis (224);
CCR3 and CCR4 for asthma and pulmonary inflammation (225–
228); CXCR4 and CCR5 for HIV infections (229, 230); and
CCR7 for pulmonary fibrosis (231). However, in the following
paragraphs, we will only focus on their potential as anti-cancer
drugs.
CHEMOKINE RECEPTORS WITH ANTIBODIES IN CLINICAL
TRIALS FOR CANCER TREATMENT
Monoclonal antibodies against CXCR4, CCR2, and CCR4 have
entered clinical trials for cancer therapy. A list of trials with these
antibodies is shown in Table 2, and antibodies against each of
these receptors and their potential in cancer therapy are described
below.
CXCR4
As demonstrated by a plethora of publications, CXCR4 has a key
role in fundamental aspects of cancer, including proliferation,
migration, invasion, and angiogenesis (35, 69–76, 234–237), lead-
ing to a number of programs to develop therapeutic anti-CXCR4
antibodies. The most advanced candidate is MDX-1338, an anti-
CXCR4 mAb also known as BMS-936564 (owned by Bristol-Myers
Squibb Co.). It was raised on human Ig transgenic mice immu-
nized with human CXCR4-transfected mouse cells (232). This
antibody (IgG4) blocks CXCL12 binding to its receptor with high
affinity, and inhibits CXCL12-induced migration and calcium flux.
MDX-1338 shows anti-tumoral activity in xenografts of acute
myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and
multiple myeloma. In vitro assays showed that the antibody trig-
gers tumor cell apoptosis, allowing to propose it as one of the
mechanisms of tumor growth inhibition (232).
MDX-1338 is currently undergoing two Phase I stud-
ies. The first-in-human study (ClinicalTrials.gov Identifier:
NCT01120457) started in 2010 and was planned to be accom-
plished by the end of 2014 and to enroll up to 82 patients. This
anti-CXCR4 mAb is being evaluated as a monotherapy and com-
bined with chemotherapy to treat patients with relapsed/refractory
AML, diffuse large B-cell leukemia, chronic lymphocytic leukemia
(CLL), or follicular lymphoma. The aim of the trial is to deter-
mine the safety, tolerability, maximum tolerated dose, prelim-
inary pharmacodynamics, and efficacy. A second Phase I trial
(NCT01359657) started in 2011 to determine safety and toler-
ability of MDX-1338 as monotherapy or in combination with
lenalidomide/dexamethasone or bortezomib/dexamethasone in
subjects with relapsed/refractory multiple myeloma. This study
is planned to enroll up to 64 patients and be finished in 2015.
Other antibody-derived molecules targeting CXCR4 are being
evaluated in clinical trials. This is the case for ALX-0651 (owned by
Ablynx, Belgium), a biparatopic anti-CXCR4 nanobody, directed
against two different epitopes of CXCR4 (32). Nanobodies are
single-domain proteins, derived from the antibody-binding frag-
ment of camelid antibodies. Their immunoglobulins are devoid of
light chains and possess only heavy-chains. Nanobodies have the
advantages of their relative small size (12–15 kDa) and high solu-
bility, which allows them to cross tissue barriers easily than mam-
malian immunoglobulins (with a 10-fold higher M.W.). ALX-0651
effectively mobilizes hematopoietic stem cells in a pre-clinical
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Table 2 | Anti-chemokine receptors antibodies for cancer therapy in clinical trials.
mAb name; mAb class;
mAb actions
Chemokine
receptor
Clinical trial identifier;
start date; intervention
Phase Condition Country Status;
completion
date
Company/
sponsor
MDX-1338 (232),
BMS-9365649,
ulocuplumab; fully human,
IgG4; neutralization,
apoptosis induction
CXCR4 NCT01359657a; 2011;
monotherapy or combined with
lenalidomide, dexamethasone,
or bortezomib
I Multiple myeloma United States Active, not
recruiting
Bristol–Myers
Squibb
NCT01120457a; 2010;
monotherapy
I AML, DLBCL, CLL, follicular
lymphoma
United States Active, not
recruiting
Bristol–Myers
Squibb
MLN1202 (224);
humanized, IgG1;
neutralization
CCR2 NCT01015560a; 2010;
monotherapy
II Bone metastases United States Completed
2012
Millenium-Takeda/
Southwestern
Oncology Group
KW-0761 (233), AMG 761,
mogamulizumab;
humanized, IgG1; ADCC
CCR4 UMIN000010050b,
NCT01929486a; 2013;
monotherapy
Ia/Ib Advanced or recurrent CCR4−
cancer (effect of Treg cell
depletion)
Japan Recruiting Kyowa Hakko Kirin
Pharma, Inc.
UMIN000013294b; 2013;
prognostic study of patient who
completed Study
NCT01173887a
II CCR4+ ATLL Japan Not longer
recruiting
Kyowa Hakko Kirin
Pharma, Inc.
NCT01626664a; 2012; KW0761
or investigator’s choiced
II Relapsed or refractory ATLL United States, Belgium, Brazil,
France, Peru, United Kingdom
Recruiting Kyowa Hakko Kirin
Pharma, Inc.
NCT01728805a; 2012;
monotherapy vs. vorinostat
III Relapsed or refractory CTCL United States, Australia, Denmark,
France, Germany, Italy, Japan,
Netherlands, Spain, Switzerland,
United Kingdom
Recruiting Kyowa Hakko Kirin
Pharma, Inc.
NCT01611142a, 2011-004151-39c;
2012; monotherapy
II Relapsed or refractory CCR4+
PTCL
Denmark, France, Italy, Netherlands,
Spain, Germany, United Kingdom
Active, not
recruiting
Kyowa Hakko Kirin
Pharma, Inc.
NCT01173887a; 2010; Compare
mLSG15+KW-0761 to mLSG15
II Untreated CCR4+ ATLL Japan Completed Kyowa Hakko Kirin
Pharma, Inc.
NCT01226472a; 2010;
monotherapy
II Relapsed PTCL, CTCL, including
mycosis fungoides and Sezary
Syndrome
United States Completed Kyowa Hakko Kirin
Pharma, Inc.
NCT01192984a; 2010;
monotherapy
II Relapsed CCR4+ peripheral
T/NK-cell lymphoma
Japan Completed Kyowa Hakko Kirin
Pharma, Inc.
NCT00920790a; 2009;
monotherapy
II Relapsed CCR4+ ATLL, Japan Completed Kyowa Hakko Kirin
Pharma, Inc.
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cynomolgus monkey model (32). A Phase I study of safety and
effectiveness for this nanobody in healthy volunteers started in
2011 (NCT01374503), but no results have yet been reported.
In addition, many pre-clinical reports have demonstrated the
in vivo relevance of CXCR4 as a target for cancer therapy. An
early report by Müller and co-workers demonstrated a key role
for chemokine receptors in metastasis, linking the expression
of CXCR4 in breast carcinomas with their ability to generate
regional lymph node and lung metastases (35). These data were
supported by experiments in which a neutralizing anti-human
CXCR4 antibody (clone 44717.111) led to a significant decrease
in lung, inguinal, and axillary lymph node metastases. This work
highlighted that chemokine interactions with chemokine recep-
tors might turn to be crucial for breast cancer metastasis, show-
ing that antibodies anti-CXCR4 may be useful to interfere with
tumor progression and metastasis. Subsequently, similar results
were obtained treating xenografts of a human NHL (26) and of
a primary human AML (38) with another anti-human CXCR4
antibody (clone 12G5). In both models, a significant reduc-
tion on tumor progression was reported. In endometrial cancer
xenografts, treatment with 12G5 mAb led to a complete inhibi-
tion of spontaneous metastases in liver and lung, and a 28-fold
decrease in metastatic index in the peritoneum (30). Interestingly,
on an intratibial human osteosarcoma xenograft model, 12G5
mAb reduced metastatic spread to the lung (27).
CCR2
CCR2 expression in tumor cells facilitates prostate and breast can-
cer metastases to the bone, where its ligand CCL2 is expressed
(155, 238). Prostate cancer patients with bone metastases had
higher CCL2 serum levels than patients with localized tumors
(155). In vitro and in vivo experiments using CCR2 or CCL2
knocked down prostate cancer cells demonstrated that these pro-
teins promote prostate cancer growth in bone (238). Similarly,
breast cancer metastasis to bone and lung is facilitated by CCL2
interaction with the CCR2+ stromal cells of monocytic origin,
including macrophages and pre-osteoclasts (238). MLN1202, a
humanized, neutralizing anti-CCR2 mAb (224) (developed by
Millenium Pharmaceuticals Inc., currently Takeda Pharmaceuti-
cals Co.) went through a Phase II clinical trial for the treatment
of bone metastases (NCT01015560). MLN1202 was administered
to 44 patients with bone metastasis to address its effect on tumor
cell proliferation, monocyte/macrophage trafficking, and osteo-
clast maturation. Forty-one out of 43 eligible patients completed
this study, with 7% having serious adverse events. The concentra-
tion in urine of the n-telopeptide, a biomarker to measure bone
turnover rates, decreased in 14% of the patients after 43 days of
MLN 1202 treatment, suggesting a positive effect of the antibody
in these patients.
CCR4
CCR4 is a chemokine receptor predominantly expressed on type 2
T helper cells (Th2), Foxp3+ regulatory T-cells (Treg), a subset of
CD4+ Th17 cells, and skin-homing T-cells positive for cutaneous
lymphocyte antigen (CLA) (239–243). This receptor binds two lig-
ands, CCL17 (formerly TARC) and CCL22 (formerly MDC), and
has been implicated in the pathology of inflammatory diseases and
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cancer, being over-expressed on many malignant ATL, CTCL, and
PTCL cells (161–163).
The antibody KW-0761 (mogamulizumab), a derivative of the
mouse KM2160 mAb, is a humanized defucosylated IgG1 mAb
targeting CCR4 (developed by Kyowa Hakko Kirin Co.) (233).
KM2160, its chimera KM2760 and the humanized version KW-
0761 recognize the N-terminal region of human CCR4 (163, 233,
244). They neither block the interaction between CCR4 and their
ligands nor inhibit CCR4 signaling (233). Defucosylation increases
Fc-binding to the Fcγ receptors expressed on cytotoxic cells, acti-
vating them for tumor cell killing (245). In fact, KM2760 showed
potent anti-tumor activity in mouse xenografts of CCR4+ cell lines
derived from patients diagnosed of ATL, Hodgkin lymphoma, or
CTCL (242, 246, 247). In addition, this mAb showed enhanced
ADCC against primary CCR4+ ATL cells both in vitro and in vivo
in an autologous setting (163, 233, 246). A phase I clinical trial of
KW−0761 for patients with relapsed CCR4+ PTCL or ATL was
the first one to examine the safety and efficacy of a new gener-
ation defucosylated therapeutic antibodies for cancer treatment
(NCT00355472) (248).
KW-0761 was approved for therapeutic use in Japan for
relapsed or refractory CCR4+ ATL in 2012, and for relapsed
or refractory CCR4+ PTCL or CTCL in 2014, representing the
first approved antibody drug against GPCR receptors being used
for cancer therapy. In other countries, there are several clinical
trials currently under way, such as a Phase II (NCT01611142)
for patients with relapsed or refractory PTCL, and a Phase III
for the comparison of progression-free survival, after treatment
with either KW-0761 or vorinostat (a chemical inhibitor of his-
tone deacetylases), on patients with previously treated CTCL
(NCT01728805). Despite the positive effects of mogamulizumab
in resistant/refractory ATL, PTCL, or CTCL, the application for its
use in untreated CCR4+ ATL was withdrawn by the company, on
February 2014.
A therapeutic potential for mogamulizumab has been sug-
gested against Epstein–Barr virus (EBV)-associated T- and NK-cell
lymphoproliferative diseases, which can be refractory to conven-
tional chemotherapies (249). In particular, since this mAb induced
ADCC activity against CCR4+ EBV+-T and -NK-cell lines, and
inhibited the growth of EBV+ NK-cell lymphomas in xenografts
(249).
It is known that Treg cells can facilitate tumor cell evasion from
immune surveillance (250). Since CCR4 is expressed on Treg cells,
it was conceivable that treatments targeting CCR4 might affect
Treg cells. On CTCL patients, a single dose of mogamulizumab has
been shown to reduce the fraction of CCR4+ malignant T-cells,
with a concomitant reduction of CCR4+ Treg cells. Interestingly,
the reduction of Treg cells may, in turn, improve the immune
profiles of these patients (251). KM2760 has also been used, in co-
treatment with NK cells, for the in vitro elimination of Treg cells
(252). A patient treated with mogamulizumab suffered serious
adverse reactions and the Stevens–Johnson syndrome (a milder
form of toxic epidermal necrolysis), probably due to a signifi-
cant reduction of its Treg cells (253). A positive interpretation of
these results would suggest, however, that anti-CCR4 mAbs could
be used on CCR4− tumors to deplete Treg cells from circulation
and infiltrating the tumor mass. Indeed, a phase I clinical trial
of mogamulizumab for CCR4− solid cancers (UMIN000010050),
specifically aiming to deplete Treg cells is currently under way
(253). Other adverse effects of mogamulizumab include cutaneous
reactions that improve over time (254), the reactivation of hepatitis
B virus (255), or diffuse panbronchiolitis (256).
There are other anti-CCR4 mAbs being screened on discov-
ery or pre-clinical phases. Among them, mAb1567 is a humanized
neutralizing anti-CCR4 antibody that exhibits potent anti-CCR4+
CTCL tumor activity in xenografts, where it displays in vitro CDC
and neutrophil-mediated ADCC. mAb1567 also exerts in vitro
human NK cell-mediated ADCC (29). In addition, SCID-beige
mice expressing an adenovirus construct derived from mAb1567
allowed an effective in vivo treatment of CTCL (257). Further-
more, mAb2–3, an affinity-optimized variant of the humanized
mAb1567, has been selected for further pre-clinical development
(29). Human anti-CCR4 antibodies, generated by phage display
(17G and 9E), also show in vitro efficient killing of CCR4+
tumor cells via ADCC and phagocytosis, and improved survival in
xenografts (31).
CHEMOKINE RECEPTORS WITH ANTIBODIES IN DISCOVERY
OR PRE-CLINICAL ASSAYS FOR CANCER TREATMENT
CXCR2
CXCR2 and its ligands, the chemokines CXCL1, CXCL2, CXCL3,
CXCL5, CXCL6, CXCL7, and CXCL8, are expressed by a wide
variety of human cancer types (41, 258). CXCR2 is a potent pro-
tumorigenic receptor that mediates the recruitment of immuno-
suppressive leukocytes into tissues, in particular of neutrophils
(259). Immunopathological analyses demonstrated the expres-
sion of high levels of CXCR2 and its ligand CXCL5 in pancreatic
tumors (33). Thus, it was conceivable that treatment with anti-
CXCR2 antibodies would inhibit leukocyte infiltration and their
pro-tumoral activities. Indeed, treatment with neutralizing anti-
mouse CXCR2 antibodies of human pancreatic tumors growing
as xenografts displayed reduced tumor volumes, decreased pro-
liferation indexes, and microvessel densities (33, 260). The pan-
creatic tumor cell line used in that model was devoid of CXCR2
expression (261). CXCR2 can also be expressed on endothelial
cells (262), where it can mediate angiogenesis (263). These data,
together with a series of in vitro assays demonstrating an anti-
angiogenic role for antagonist anti-CXCR2 mAbs in endothelial
cells (260), suggested that inhibition of tumor growth in the
xenograft model was due to angiogenesis inhibition mediated by
these antibodies.
CXCR5
A different approach was used to target CXCR5. In this case, a bis-
pecific Ab, containing paratopes recognizing CXCR5 on the one
side and the CD3-T-cell co-receptor on the other, was used (36).
With this tool, the authors were able to bring together the tumor
cell, recognized with the anti-CXCR5 paratope, with a T lym-
phocyte, recognized with the anti-CD3 paratope, maintaining the
ability of the antibody to bind cells of the innate immune response
through the Fc region, potentiating in this way the anti-tumoral
response (36). This bispecific antibody was highly efficient lysing
tumor cells at low concentrations not only in vitro but also in vivo
on xenograft models of B-cell lymphoma (36).
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CCR7
In subcutaneously injected human mantle cell lymphoma (MCL)
cells on mice, anti-CCR7 treatment caused a significant delay on
tumor growth and metastasis generation. It also hindered lym-
phoma cell dissemination in intravenous injections (37). The data
obtained were compatible with both decreased infiltration of MCL
cells into different tissues and the induction of anti-MCL cell
cytotoxicity in mice. Anti-CCR7 therapy might be indicated for
patients carrying CCR7+ B-cell NHL or CLL (37).
CCR9
We have reported the generation and characterization of 91R, a
mouse anti-human CCR9 mAb able to reduce 85% human T
lymphoblastic cell tumors on mice. Tumor size reduction was
concomitant with an increased apoptotic tumor cell fraction and
tumor necrotic areas, as well as decreased fraction of prolifer-
ating cells and tumor vascularization. It is likely that CDC or
ADCC represent the in vivo mechanisms of action of this mAb
(28). These results suggest that CCR9-expressing tumors, such as
acute and chronic T-cell lineage leukemia (180), prostate cancer
(181), breast cancer (182), and melanomas (183), can potentially
be targeted with this mAb.
ACKR3 (FORMERLY CXCR7)
Anti-ACKR3 nanobodies inhibited tumor growth of ACKR3+
head and neck cancer cells, reducing expression of the endothe-
lial cell marker CD31 in the tumors growing as xenografts. These
data were corroborated by in vitro analyses demonstrating that
anti-ACKR3 nanobodies rather than affecting cell cycle progres-
sion, reduced the secretion of the angiogenic chemokine CXCL1
by the tumor cells, suggesting that anti-ACKR3 nanobodies could
inhibit tumor vascularization. This work proposes anti-ACKR3
therapies as potential novel treatments against ACKR3+ head and
neck cancer (34).
The antibodies described so far are representative of the use
of anti-chemokine receptor antibodies for cancer treatment, but
they represent only the tip of the iceberg, since many compa-
nies describe in their web pages, or have already presented in
specialized meetings their efforts for developing new antibod-
ies. Some of these antibodies are AT008 (anti-CCR4) and AT009
(anti-CXCR4) from Affitech; anti-CXCR5, anti-CCR2, and anti-
CXCR3 from Sorrento Therapeutics Inc.; anti-CXCR4 (515H7)
from Pierre Fabre (264); and anti-CXCR4 (CX-02 and CX-05)
from NorthWest Biotherapeutics Inc. (265).
CONCLUSION AND PERSPECTIVES
Chemokines and their receptors, in addition to their role on physi-
ological responses, directing the cells toward specific sites, allowing
lymphocyte maturation, survival, proliferation, and migration,
they play a key role in cancer initiation, angiogenesis, tumor
growth, progression, and metastasis. The over-expression by many
tumors of chemokine receptors turns them and their ligands into
clear targets for cancer therapy, on the initial assumption that
inhibition of chemokine signaling might block tumor progression
and/or metastasis.
The development of small molecules able to inhibit chemokine
receptor signaling has shown limited success, with the exception
of plerixafor (AMD3100), which by blocking binding of CXCL12
to CXCR4 mobilizes CXCR4+ cells, including CXCR4+ tumor
cells, from the bone marrow to circulation (266, 267). Plerix-
afor enhances sensitivity of tumor cells to cytotoxic agents by
disrupting interaction with the tumor microenvironment (268–
271). Since therapeutic mAbs have provided clinical benefits to
cancer patients during the last decade, therapeutic antibodies
against chemokine receptors seemed a good alternative. The recent
technological advances allowed the generation of highly specific,
high affinity antibodies against these receptors that are currently
entering the clinics.
This “theoretical” view suggesting that anti-chemokine recep-
tor mAbs might represent an efficient way to treat cancer was fully
supported by the recent approval in Japan of mogamulizumab for
the treatment of ATL. It is so far the only anti-GPCR therapeutic
antibody in the market and represents the proof-of-principle for
the therapeutic use of mAbs targeting GPCRs, as on chemokine
receptors, leading to clinical benefits on cancer patients.
Chemokine receptors are expressed, in addition to endothe-
lial cells, on the tumor and on cells from the immune system,
responsible for defending from the tumor. Therefore, any drug or
antibody targeting a given chemokine receptor will act on both the
tumor and immune system cells expressing it. In the case of moga-
mulizumab, raised against CCR4, it should be noted that there is
only a fraction of T lymphocytes (within the Th2, Treg, and Th17
phenotypes) that are CCR4+, representing the few non-tumoral
targets for this antibody. Since the phenotypes affected include
Treg and Th17 cells, their elimination would become advantageous
for treating the tumor, as the immunosuppressive responses would
be reduced. Treatment with antibodies against other chemokine
receptors such as CXCR4 or CCR7 might have a broad effect on the
host immune response, since there is a large fraction of leukocytes
expressing them. This effect is not necessarily beneficial in terms
of reducing tumor size.
These data raise the question whether other anti-chemokine
receptors can be safely used as targets for tumor treatment. In
particular, it should be determined, for each chemokine recep-
tor, whether there are therapeutic doses of an antibody able to
effectively kill tumor cells or cells favoring tumor growth, while
not affecting the normal cells from the immune system express-
ing that particular receptor. In other words, the aim is to find
the therapeutic window where tumor cells are safely destroyed
whereas the immune cells are not. This can be exemplified with
data on CCR2+ tumor infiltrating cells, where if the infiltrating
cells are macrophages supporting the metastatic dissemination of
malignant cells, the anti-CCR2 treatment may be effective. Con-
versely, if the infiltrating cells are CD8+ and γδ effector T-cells
that enhance immuno-surveillance by triggering Th1 responses,
the treatment might turn deleterious (272, 273).
Thus, the complex network between chemokine receptors and
their ligands, together with the simultaneous expression of a given
receptor on cells of the immune system and on the tumor (includ-
ing tumor cells, stroma cells, and/or tumor infiltrating cells) and
the dichotomy of their responses clearly represent the lights and
shadows of the potential of anti-chemokine receptor therapeu-
tic antibodies for the treatment of tumors. The optimal situation
would be to have a panel of therapeutic antibodies against different
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chemokine receptors. These antibodies could be used, depending
on the tumor phenotype, in particular combinations (personalized
medicine) at relatively low doses for each one of them, minimizing
the probability of affecting the normal cells.
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